NeuroDerm (NDRM) Announces Top-Line Data from ND0701 PK Trial; Results Comparable to Reference Drug
Tweet Send to a Friend
NeuroDerm Ltd. (Nasdaq: NDRM) announced the completion of a pilot study (trial 101) in healthy subjects comparing the pharmacokinetics (PK) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
